Literature DB >> 34657128

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.

Anthony V Moorman1, Emilio Barretta2, Ellie R Butler2, Eleanor J Ward2, Katie Twentyman2, Amy A Kirkwood3, Amir Enshaei2, Claire Schwab2, Tom Creasey2, Daniel Leongamornlert4, Elli Papaemmanuil5, Pip Patrick3, Laura Clifton-Hadley3, Bela Patel6, Tobias Menne7, Andrew K McMillan8, Christine J Harrison2, Clare J Rowntree9, David I Marks10, Adele K Fielding11.   

Abstract

Chromosomal abnormalities are established prognostic markers in adult ALL. We assessed the prognostic impact of established chromosomal abnormalities and key copy number alterations (CNA) among 652 patients with B-cell precursor ALL treated on a modern MRD driven protocol. Patients with KMT2A-AFF1, complex karyotype (CK) and low hypodiploidy/near-triploidy (HoTr) had high relapse rates 50%, 60% & 53% and correspondingly poor survival. Patients with BCR-ABL1 had an outcome similar to other patients. JAK-STAT abnormalities (CRLF2, JAK2) occurred in 6% patients and were associated with a high relapse rate (56%). Patients with ABL-class fusions were rare (1%). A small group of patients with ZNF384 fusions (n = 12) had very good survival. CNA affecting IKZF1, CDKN2A/B, PAX5, BTG1, ETV6, EBF1, RB1 and PAR1 were assessed in 436 patients. None of the individual deletions or profiles were associated with survival, either in the cohort overall or within key subgroups. Collectively these data indicate that primary genetic abnormalities are stronger prognostic markers than secondary deletions. We propose a revised UKALL genetic risk classification based on key established chromosomal abnormalities: (1) very high risk: CK, HoTr or JAK-STAT abnormalities; (2) high risk: KMT2A fusions; (3) Tyrosine kinase activating: BCR-ABL1 and ABL-class fusions; (4) standard risk: all other patients.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34657128      PMCID: PMC8885405          DOI: 10.1038/s41375-021-01448-2

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  1 in total

1.  Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.

Authors:  Jian-Feng Li; Yu-Ting Dai; Henrik Lilljebjörn; Shu-Hong Shen; Bo-Wen Cui; Ling Bai; Yuan-Fang Liu; Mao-Xiang Qian; Yasuo Kubota; Hitoshi Kiyoi; Itaru Matsumura; Yasushi Miyazaki; Linda Olsson; Ah Moy Tan; Hany Ariffin; Jing Chen; Junko Takita; Takahiko Yasuda; Hiroyuki Mano; Bertil Johansson; Jun J Yang; Allen Eng-Juh Yeoh; Fumihiko Hayakawa; Zhu Chen; Ching-Hon Pui; Thoas Fioretos; Sai-Juan Chen; Jin-Yan Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-28       Impact factor: 11.205

  1 in total
  6 in total

1.  Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience.

Authors:  Guillaume Richard-Carpentier; Hagop M Kantarjian; Guilin Tang; C Cameron Yin; Joseph D Khoury; Ghayas C Issa; Fadi Haddad; Nitin Jain; Farhad Ravandi; Nicholas J Short; Courtney D DiNardo; Koichi Takahashi; Marina Y Konopleva; Naval G Daver; Tapan Kadia; Guillermo Garcia-Manero; Rebecca Garris; Susan O'Brien; Elias Jabbour
Journal:  Blood Adv       Date:  2021-12-14

2.  Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Helena Hohtari; Niels Pallisgaard; Matti Kankainen; Pekka Ellonen; Oscar Brück; Timo Siitonen; Marjaana Säily; Marjatta Sinisalo; Marja Pyörälä; Maija Itälä-Remes; Perttu Koskenvesa; Erkki Elonen; Satu Mustjoki; Kimmo Porkka
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

Review 3.  Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia.

Authors:  Yang Song; Qiuyun Fang; Yingchang Mi
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

4.  Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.

Authors:  Thomas Creasey; Emilio Barretta; Sarra L Ryan; Ellie Butler; Amy A Kirkwood; Daniel Leongamornlert; Elli Papaemmanuil; Pip Patrick; Laura Clifton-Hadley; Bela Patel; Tobias Menne; Andrew K McMillan; Christine J Harrison; Clare J Rowntree; Nick Morley; David I Marks; Adele K Fielding; Anthony V Moorman
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

Review 5.  Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL).

Authors:  Tina Künz; Alexander W Hauswirth; Gabriele Hetzenauer; Jakob Rudzki; David Nachbaur; Normann Steiner
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

6.  Clinical and Prognostic Impact of Copy Number Alterations and Associated Risk Profiles in a Cohort of Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Cases Treated Under ICiCLe Protocol.

Authors:  Sanjeev Kumar Gupta; Minu Singh; Pragna H Chandrashekar; Sameer Bakhshi; Amita Trehan; Ritu Gupta; Rozy Thakur; Smeeta Gajendra; Preity Sharma; Sreejesh Sreedharanunni; Manupdesh S Sachdeva; Deepam Pushpam; Neelam Varma; Deepak Bansal; Richa Jain; Srinivasan Peyam; Anthony V Moorman; Prateek Bhatia
Journal:  Hemasphere       Date:  2022-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.